Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8IV42

UPID:
PSTK_HUMAN

ALTERNATIVE NAMES:
O-phosphoseryl-tRNA(Sec) kinase

ALTERNATIVE UPACC:
Q8IV42; Q6ZSS9

BACKGROUND:
The enzyme L-seryl-tRNA(Sec) kinase, alternatively named O-phosphoseryl-tRNA(Sec) kinase, is integral to the unique selenocysteine incorporation pathway. By phosphorylating seryl-tRNA(Sec), it activates an intermediate necessary for the production of selenocysteine, the 21st amino acid, which is incorporated into selenoproteins.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of L-seryl-tRNA(Sec) kinase could open doors to potential therapeutic strategies. Given its essential role in the biosynthesis of selenocysteine, targeting this kinase could lead to novel approaches in managing conditions associated with selenoprotein dysfunction, highlighting its potential as a therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.